APP and Alzheimer disease: Activation of the NLRP3 inflammasome contributes to Aβ accumulation, synaptic dysfunction, and cognitive impairment in APP/PS1 mice, suggesting that blocking the assembly of the inflammasome may constitute a novel therapeutic intervention for attenuating changes that negatively affect neuronal function in AD (Dempsey et al., 2017).